At Dicronis GmbH, we strive to enhance the quality-of-life of patients with our innovative technology.
The first product in our pipeline, enables the quantitative assessment of the lymphatic function of the patient in a safe, home-based and highly scalable manner.
The initial indication of our first product is the earliest possible diagnosis of secondary lymphedema, a serious side effect of many cancer therapies.
By remotely monitoring the lymphatic function, the doctor is empowered for the first time to perform an early diagnosis, before any swelling of a limb has occurred, and timely prescribe the best conservative treatment for the patient.
This leads to a great improvement of the prognosis and quality of life of the patient and important savings for the healthcare system and society.
Dicronis GmbH is currently scaling-up the GMP production of the microneedles and completing the development of the assisting wearable device, in view of the clinical transition, planned for middle of 2020 in collaboration with a clinical partner.
The patented platform technology, featuring fluorescent microneedles for a measure of the dermal lymphatic function will allow to improve the quality of life of millions of cancer survivors worldwide.
Check our latest achievements and news
The Team of Dicronis is proud to have been selected among the finalist of the prestigious ZKB Pioneerpreis TECHNOPARK® Zurich, organised by the Zürcher Kantonalbank (The Cantonal Bank of Zurich.....
April 15, 2019
It was a great opportunity for Patrizia to present our company at the Merck Start-Up Days. The event was moderated by Dan Ram, renowned entrepreneur, speaker, artist and coach, welcomed around 200 innovators among which we found startups, curious minds,.....
April 10, 2019
Dr. Jabinet had the chance to gain insight from the most influential experts in the evolving regulatory field, coming from both governmental agency and industry. This field is of great interest for the development of Lymphit,......
April 04, 2019